Lausmed Kft.

Clinical trials at this research site focus strongly on cardiovascular diseases, especially atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, and broader high cardiovascular risk populations. The studies are mainly designed to test new ways to reduce major heart-related events and improve long-term outcomes.

• Preventing heart attack, stroke, and other major cardiovascular events
• Evaluating treatments for atrial fibrillation and clot-related complications
• Improving care for people with established cardiovascular disease or elevated risk

This area reflects a clear emphasis on better protection against serious cardiovascular outcomes and more effective management of chronic heart disease.

Another major theme is nutritional and metabolic diseases, with trials addressing type 2 diabetes, obesity, mixed dyslipidemia, hyperlipidemia, and severe triglyceride disorders. These studies are exploring whether new therapies can improve blood sugar control, support weight management, and correct harmful lipid levels.

• Testing treatments for type 2 diabetes and inadequate glucose control
• Studying weight loss approaches in obesity and overweight populations
• Evaluating therapies for high triglycerides and abnormal cholesterol profiles

The work in this field aims to address interconnected metabolic problems that often increase the risk of later cardiovascular disease.

The site also contributes to studies linking chronic kidney disease with diabetes, obesity, and cardiovascular complications. These trials are focused on understanding whether new treatments can slow disease progression and lower the burden of combined cardiometabolic illness.

• Assessing approaches to reduce kidney damage in people with diabetes and excess weight
• Exploring therapies for patients with overlapping heart, kidney, and metabolic conditions
• Supporting research on earlier intervention in complex chronic disease

This research area is especially relevant for patients whose kidney health and cardiovascular risk are closely connected.

A smaller but important part of the portfolio includes trials targeting specific risk factors such as elevated lipoprotein(a), hypertension, and other conditions where improved prevention strategies are needed. These studies aim to refine how clinicians identify risk and choose treatments that may prevent first or recurrent major events.

• Investigating therapies for elevated lipoprotein(a) and residual cardiovascular risk
• Studying blood pressure control in people with difficult-to-manage hypertension
• Advancing prevention-focused research for people without prior major events

At Lausmed Kft., this research supports more precise prevention in people who may not yet have had a major event but remain at substantial risk.